$BIIB Recent Headlines Biogen results crush consensus

New Post Public Reply Private Reply Replies (0) Message Board

Jul 24, 2014 at 11:07 AM

$BIIB Recent Headlines

Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
S&P 500 closes at record on strong earnings 4:23 p.m. July 23, 2014 - Anora Mahmudova
Apple, Intuitive power S&P 500 to record: stock market live blog recap 4:17 p.m. July 23, 2014 - blogs.marketwatch.com
Biogen rallies on earnings; Juniper slumps 10% 1:25 p.m. July 23, 2014 - Sue Chang
Biogen earnings: A lesson in how to boost an already pricey stock 10:49 a.m. July 23, 2014 - Russ Britt
Biogen Idec shares rally 12% 9:32 a.m. July 23, 2014 - Sue Chang
Biogen Idec shares up 7% in premarket trade after earnings 7:39 a.m. July 23, 2014 - Ciara Linnane
Biogen Idec's profit, sales blow past estimates 7:20 a.m. July 23, 2014 - MarketWatch.com
Biogen Idec shares rally 5.4% in premarket trade after earnings 6:53 a.m. July 23, 2014 - Tomi Kilgore
One lesson for investors from the 1990s bubble 3:13 p.m. June 19, 2014 - The Trading Deck
Tyson rallies after jumping into Hillshire chase 3:44 p.m. May 29, 2014 - Sue Chang
TripAdvisor leads momentum-play rally to lift Nasdaq 3:52 p.m. May 12, 2014 - Sue Chang
Wall Street up for second day on earnings cheer; biotechs rebound: Stock market live blog recap 4:03 p.m. April 29, 2014 - blogs.marketwatch.com
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
Investors gloss over Biogen earnings miss and focus on MS drug sales 2:23 p.m. April 23, 2014 - Russ Britt
Scouring the moonscape for leading stocks 3:02 p.m. April 22, 2014 - The Trading Deck
Apple, Microsoft are not the keys to this week’s news 7:00 a.m. April 22, 2014 - Marek Fuchs
Long view on stocks is best during weak earnings season 6:00 a.m. April 20, 2014 - Wallace Witkowski
Biotech misses out on Nasdaq rally, sinks further into bear ground 4:58 p.m. April 14, 2014 - Russ Britt
Herbalife sinks on probe fears; Zoe’s surges on debut 4:37 p.m. April 11, 2014 - Sue Chang

Stock Market News for July 24, 2014 - Market News 57 min ago - Zacks.com
Gilead Crushes Q2 Earnings Estimates as Sovaldi Sales Soar - Analyst Blog 9:50 a.m. Today - Zacks.com
Zacks Rank #1 Additions for Thursday - Tale of the Tape 9:30 a.m. Today - Zacks.com
The Medicines Co.'s (MDCO) Q2 Earnings Decline Y/Y - Analyst Blog 9:20 a.m. Today - Zacks.com
Array BioPharma, Inc. (ARRY) Jumps: Stock Surges 10.7% Higher - Tale of the Tape 9:11 a.m. Today - Zacks.com
Biogen Idec (BIIB) Soars: Stock Adds 11.2% in Session - Tale of the Tape 8:51 a.m. Today - Zacks.com
Time to Focus on Biogen Idec (BIIB) for Strong Earnings Growth Potential - Tale of the Tape 8:48 a.m. Today - Zacks.com
Cramer's Mad Money: The 4 Horsemen Trample Big Pharma (7/23/14) 6:01 a.m. Today - Seeking Alpha
Jim Cramer's Top Stock Picks: PEP CELG GILD REGN BIIB CMG 6:00 a.m. Today - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Unconventional Wisdom 8:05 p.m. July 23, 2014 - TheStreet.com
Avanir to Conduct Phase II Study on AVP-786 for Depression - Analyst Blog 5:50 p.m. July 23, 2014 - Zacks.com
Biogen, Gilead Crush Earnings Estimates On Hot Drugs 5:17 p.m. July 23, 2014 - Investors Business Daily
10-Q: BIOGEN IDEC INC. 4:24 p.m. July 23, 2014 - Edgar Online - (EDG = 10Q, 10K)
Can't Find an Edge 4:20 p.m. July 23, 2014 - RealMoney.com
Biogen's Results Cure Some Pain 4:00 p.m. July 23, 2014 - Seeking Alpha
Biogen Idec's (BIIB) CEO George Scangos on Q2 2014 Results - Earnings Call Transcript 3:52 p.m. July 23, 2014 - Seeking Alpha
Biogen Idec Beats And Raises: Reassessing Its Prospects 3:43 p.m. July 23, 2014 - Seeking Alpha
IPO Stock Watch: Biotechs Are Half Of July Calendar 3:07 p.m. July 23, 2014 - Investors Business Daily
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog 2:15 p.m. July 23, 2014 - Zacks.com
Biogen Trounces Q2 Estimates As Tecfidera Outperforms 10:56 a.m. July 23, 2014 - Investors Business Daily

PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis 11:41 a.m. July 23, 2014 - BusinessWire - BZX
Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 12:00 p.m. July 22, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept 8:40 a.m. July 17, 2014 - PR Newswire - PRF
Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS) 8:01 a.m. July 16, 2014 - BusinessWire - BZX
Biotech Equities under the Scanner -- Research on Alexion Pharma, InterMune, Cytokinetics, and Biogen Idec 5:55 a.m. July 7, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
RBCC Developing New Tech to Help Prevent Deaths From Prescription Overdoses 5:00 a.m. July 2, 2014 - BusinessWire - BZX
Biogen Idec to Report Second Quarter 2014 Financial Results on July 23, 2014 4:01 p.m. June 30, 2014 - BusinessWire - BZX
Critical Alerts For Vertex Pharmaceuticals, Dollar Tree, Avis, Ryder, and Biogen Released By InvestorsObserver 9:31 a.m. June 25, 2014 - PR Newswire - PRF
True North Therapeutics Announces $22 Million Series A Financing 7:00 a.m. June 17, 2014 - BusinessWire - BZX
Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec 7:00 a.m. June 17, 2014 - PR Newswire - PRF
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis 7:30 a.m. June 16, 2014 - BusinessWire - BZX
Sobi to review preclinical data to potentially add future haemophilia A candidate to collaboration agreement with Biogen Idec 2:01 a.m. June 16, 2014 - Thomson Reuters ONE
One Year Post-Launch, All Surveyed U.S. Neurologists Report Having Clinical Experience with Biogen Idec's Tecfidera for the Treatment of Multiple Sclerosis 12:00 p.m. June 12, 2014 - PR Newswire - PRF
FDA Drug Approvals, Dividends, Fast Track Designation, Event Sponsorship, and Expansion of Role - Analyst Notes on Biogen Idec, UnitedHealth Group, GW Pharmaceuticals, Questcor and Cigna 5:10 a.m. June 11, 2014 - PR Newswire - PRF
RBCC to Expand Market for 'Underused' Addiction Treatment With New Technology 5:00 a.m. June 11, 2014 - BusinessWire - BZX
The Pulmonary Fibrosis Foundation Receives Grant From Biogen Idec To Support The PFF Patient Registry 11:00 a.m. June 10, 2014 - PR Newswire - PRF
Increased Credit Facility Commitments, Positions Moved, Survey Results, LEED Certification, and New Board Member Election - Analyst Notes on Prospect, Waddell & Reed, SEI, Alexandria and RPAI 5:20 a.m. June 10, 2014 - PR Newswire - PRF
Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1 7:00 a.m. June 9, 2014 - PR Newswire - PRF
The US Food and Drug Administration (FDA) approves Eloctate(TM) 2:02 a.m. June 9, 2014 - Thomson Reuters ONE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beta Bionics Faces Class Action Lawsuit Amid FDA Concerns

Beta Bionics in the Legal Crosshairs When a company like Beta Bionics gets hauled into court, you know it's not just smoky mirrors and boardroom politics. The stakes are high right now, with investors lining up for a class-action lawsuit that zeroes in on a nasty bundle of allegations. This isn't just a blip on the radar. It's a seismic wave in the industry. Allegations...

Gala Spotlights Veterans' Mental Health Support

Champions for Veterans Honored at Headstrong Gala If you ever wondered who stands in the trenches alongside veterans facing mental health battles, this year's Headstrong Gala offered a crystal-clear answer. Held on October 16 at Pier Sixty in New York City, this shiindig wasn’t just about schmoozing over canapés. It was about celebrating the grit and guts of those...

Dimethylaminopropylamine Market Eyes $732M by 2035

Surfactants and Epoxy Fuel Dimethylaminopropylamine Demand Hot off the presses, folks! Dimethylaminopropylamine, or DMAPA if you're into acronyms, is gearing up for a steady climb to a $731.9 million market value by the year 2035. That's quite the leap from the $452.6 million we saw back in 2025. According to Credence Research's latest estimates, this amine is hitching...

FOX News Revamps 2026 Election Coverage Playbook

Revamped Coverage: More Than Just Breaking News Yeah, everyone's clamoring about the midterms, but Fox News is doing more than just flipping on the camera and breaking the news every few minutes this year. They're rolling out the big guns: AI chatbots, flashy graphics, and special shows across multiple platforms. The point? To get viewers practically hooked and give 'em...

GoldMining's 2025 Report: Zero Incidents, Big Green Goals

GoldMining Inc. Shows a Clear Green Streak Sometimes, you're caught off guard by a company's clear dedication to getting things right, and GoldMining Inc.'s latest sustainability report shows they're not just chasing fool's gold. They've laid out a solid roadmap. With the rollers they've got—swapping environmental chaos for responsible exploration—these guys have...

Egan-Jones CLO Metrics Strong Amid Rate Hikes

Interest Rates Climb, CLO Metrics Hold Firm Buckle up, folks. As interest rates drift higher like a stubborn balloon, investors are scouring the landscape for any sign of a shaky foundation. Well, here's a bit of solace in the storm: Egan-Jones, the credit rating powerhouse, has released their latest musings on the collateralized loan obligation (CLO) market...

Biotech's Future Faces Tight Investment Restrictions

Biotech Investment: Between a Rock and a Hard Place The U.S. Department of the Treasury just threw a curveball at the biotechnology sector with its proposal to shore up the Comprehensive Outbound Investment National Security (COINS) Act. This ain't just another set of lines on a folded napkin; the new rules would put a chokehold on American investments flowing into...

Endava Faces Class Action as Price Plunges 25%

Troubled Waters for Endava's Investors The corporate waters churn as Endava plc (NYSE:DAVA) finds itself slapped with a securities class action lawsuit. This legal storm rises amid talks of delayed financials and whispers of potential accounting frippery, sending shockwaves that slashed the company's stock price by a bone-rattling 25% on September 22, 2026. Now, investors...

Cboe Clear's US Move: A New Chapter with SEC Nod

Clearing the Path for New Beginnings The ink's barely dry on Cboe Clear U.S.'s recent SEC registration, and it's already setting tongues wagging among market old-timers. This move to clear binary securities options alongside futures isn't just a step up; it's a signal flare for ambitious innovation. The Nuts and Bolts: SEC Registration So, what's the big to-do? Cboe Clear...

Vinitaly.USA 2026: Italian Wine Takes Manhattan

A Two-Day Wine Extravaganza Hits New York If Italian wine was a stock, the Vinitaly.USA 2026 gathering in New York would be a rallying cry to double down. October 26-27 is set to be a whirl of handshakes and clinking glasses at Pier 36, all under the grand vision of beefing up Italy's hold on the U.S. wine market. As the compass points to growing opportunities, one can't...